A compound of cannabis could effectively kill drug-resistant superbugs.
Scientists found that cannabigerol (CBG), which is one of the more than 100 cannabinoids found in the cannabis plant, was effective in killing Staphylococcus aureus—otherwise known as MRSA.
MRSA is one of the most common antibiotic-resistant hospital superbugs that was associated with more than 19,000 deaths in 2017 alone. Bacteria can be classified as “gram positive” or “gram negative,”depending on the nature of their membrane(s), and MRSA is a gram positive bacteria. Scientists tested CBG on MRSA and it successfully killed the bug in both a lab setting and in mice.
However, the study found gram negative superbugs were much harder to treat, and CBG was initially found to be less effective against these bacteria. CBG was used in conjunction with small amounts of polymyxin B, an antibiotic that works against gram negative bacteria, and the cannabinoid was able to kill the drug-resistant bacteria.
Eric Brown, a microbiologist who led the study at McMaster University in Hamilton, Ontario, said cannabinoids were “clearly great drug-like compounds,” but still represented an early finding.
“There is much work to do to explore the potential of the cannabinoids as antibiotics from the safety standpoint,” Brown told The Guardian.
Scientists said cannabis contains many antibiotic properties to help cure different bugs.
“These are likely made as a defence mechanism to protect the plant from bacterial and fungal infections, but to date have not been very useful for human infections as they really only work outside the body,” Mark Blasovich, researcher at University of Queensland, told the Guardian. “That’s what makes this new report potentially exciting; evidence that cannabigerol is able to treat a systemic infection in mice.”
Nextleaf Solutions Ltd (CSE:OILS) (OTC: OILFF) announced that Health Canada has granted the company a Research Licence under the Cannabis Act. The license enables Nextleaf Labs to manage several research and development activities, including stability trials on the company’s nano emulsified water-soluble THC and CBD formulations.
„With a sub 10 minute onset time and no hangover symptoms, we are excited to continue to validate our intellectual property by scaling our cannabis-infused beverage technology from laboratory to commercial scale,” said CEO Paul Pedersen.
This is the second license granted to Nextleaf on behalf of Health Canada. Research licenses allow for conducting human trials for sensory evaluation.
Benzinga’s Cannabis Capital Conference returns to Miami Feb. 24-25 with North America’s largest B2B cannabis gathering, bringing together capital, cannabis executives, thought leaders and more!
The company also announced it has been issued a standard patent by IP Australia, the Australian Government agency responsible for the administration of intellectual property rights. for its filtration cell used in the post-extraction process of cannabinoids.
This patent stretches the actual company’s intellectual property portfolio. Now including proprietary filtration cell that permits the removal of undesirable compounds from crude cannabis oil more quickly and efficiently.
„One of the biggest issues with infused products relates to taste. With crude extracts and less refined oils, the consumer experience is affected by inferior taste and smell due to the presence of fats, and waxes,” said Pedersen. „We are able to solve those issues at scale with our chilled ethanol extraction and distillation processes, which is protected by 12 issued patents. We expect to double our patent portfolio in 2020, and continue to secure intellectual property around the extraction, distillation and formulation of cannabinoids.”
Cannabidiol, or CBD, is a phyto-cannabinoid found in the cannabis plant. However, unlike its siblings (marijuana and hashish), CBD does not create any kind of psychoactive effect on the brain. It is all right to agree that it is non-intoxicating in nature.
However, CBD does have many health benefits. It has successfully proven to help patients suffering from anxiety, depression, inflammation, insomnia, epilepsy, and diabetes. The best part of it all is that CBD is easily available online and stores across American. It’s available in different forms—gummies, capsules, creams, oils, vapes, etc.
CBD oil, however, is still considered to be the best way of taking CBD, especially if you are suffering from a joint or muscular pain. Sounds like a miracle cure? Well, it certainly is. However, with so many brands selling the same products, it might become challenging for a person to pick the CBD oil that suits him the best. Hence, we have compiled a list of the best CBD oil for pain relief.
Read on to learn about them.
But first, here’s all you should know about CBD oil
As discussed already, CBD is non-intoxicating in nature. The reason behind the same is that CBD doesn’t contain tetrahydrocannabinol or THC, the compound responsible for instigating the ‘high’ in your brain. So, even though, CBD oil doesn’t make you high or stoned, it does have some sleep-inducing qualities, which miraculously help in alleviating stress, anxiety, insomnia, and depression.
However, one must take into account the potency of CBD oil at the time of purchase, that is, whether it’s pure or full-spectrum CBD oil that would suit you. So, what’s the difference between the two? Full-spectrum CBD oil contains a full range of cannabinoids. On the other hand, pure CBD oil is good old CBD with no cannabinoids, terpenes, and flavonoids.
If you are wondering whether CBD is legal in the US, then you should know that under 2018 Farm Bill, CBD has been legalized in all 50 states of the nation. It has also been excluded from the list of ‘controlled substance.’ Thus, it is absolutely legal to use CBD in your food and on your body. However, it is recommended to check with your local laws before ordering CBD oil for yourself.
CBD oil and chronic pain
As per many results done in the field, CBD has the power to successfully treat chronic pains related to both muscles and joints in the body. According to a study, cannabinoids were concluded to have therapeutic effects on painful joints and muscles.
Another study done by the Journal of Experimental Medicine revealed that CBD has the characteristics that can remove pain and reduce inflammation from the body. Some of the researches also contended that CBD intake for the treatment of pain doesn’t demand to increase the dosage with time. Thus, patients can breathe a sigh of relief since the chance of building a tolerance for the intake of CBD oil is highly unlikely.
However, it is still recommended to consult your doctor or a medical expert about the dosage of CBD oil for chronic pain. The reason behind the same is that CBD is not regulated by the Food and Drug Association, thus, CBD dosage is open to interpretation. Even though there is no known side effect of CBD oil, still, it is advised to take the safer road and discuss this treatment with a medical professional.
Most people tolerate CBD oil quite well. However, if you suffer with problems, such as dizziness, tiredness, weight gain or loss, appetite change, or indigestion, then do not worry. Most of these problems disappear within a day or two.
When you use CBD medication along with other medicines, chances of side effects showing up are more. Nonetheless, it is quite uncommon for people to suffer from side effects generated by an intake of CBD oil. You will be fine and hopefully, free from your pain problems soon.
How to find the CBD oil for pain?
There is a variety of CBD oil available in the market today. So, it is important to keep in mind the reason why you actually want to consume the CBD oil. In this case, CBD oil is needed to heal all kinds of pains. Thus, you must do a lot of research on the internet about the best CBD oil and buy the product speaking.
There are a few things that you can consider before paying for the CBD oil to heal chronic pain. These considerations are clearly mentioned below-
No or low level of THC
A low potential for side effects (usually there aren’t any)
A doctor prescribed or recommended dosage of the oil
Third party lab-tested product
Full-spectrum CBD oil
As natural as possible
There are a lot of other traits to look into before buying the best CBD oil to treat pain. However, the above characteristics of the product can get you closer to alleviating the pain as possible.
Best CBD Oil for Pain?
After a thorough research, it has been contended that CBD oil which is manufactured by Fab CBD has been ranked number one by the experts. Thus, it is the best CBD oil for pain relief. It is considered to be the best for pain relief based on three traits-
Third party testing
Let’s have an individual look at the above three in relation with Fabcbd-
Concentration: The concentration of CBD oil under this brand drifts between 300 mg and somewhere around 2400mg. The oil is also available in 600 mg, and 1200 mg. This also means that you will be able to choose the strength of the oil.
Ingredient: Be assured that the presence of THC, if any, will not be more than 0.3% in the CBD oil of this brand. This brand uses the whole-plant brand, which means it goes through minimum processing and includes other cannabinoids, such as, CBG, CBC, CBDA, and CBDV. Please note that the presence of THC in the oil will not create any high. However, it might induce a sleep-inducing feeling, which is quite healing for the body.
Third-party testing: The bottles are checked for toxicity, such as herbicides, pesticides, and fungi. They are also checked for their potency and that the product fulfills all the criteria laid by the farm bill.
Here are some of the highlights of the CBD oil manufactured by FAB CBD-
Contains full-spectrum of natural cannabinoids and terpenes
Varied concentrations with best potency
Best for shoulder and knee pains
Absolutely safe to consume
The best quality of CBD oil available in the market
Note: It is a great brand product but please keep in mind to start taking it in small quantity, especially if you are a first timer. There might be a chance that you feel weird or out-of-zone for a while. However, this is just a probability, not a fact. If you experience something like the aforementioned feeling, do not worry, because it will pass away in a day or two.
Which CBD oil should you buy to treat pain problems?
Now that you know the difference between isolate or pure CBD oil and full-spectrum CBD oil, your next question will be which one would suit you best?
Well, it depends on the reason you are buying the oil. CBD pure oil is more potent in nature; it encircles around 90% of Cannabidiol and has no risk of the presence of psychoactive substances. On the other hand, full-spectrum CBD oil is more powerful as compared to pure or isolate CBD oil. It undergoes less processing and thus, is more authentic and natural.
Pure CBD oil is best in the case of –
People who are highly sensitive to the use of THC
People who want to cook in CBD oil since it doesn’t have any aroma or taste
People who are restricted to use it under the state laws
People who want to just try it
Full-spectrum is recommended for –
People who want to buy it for some targeted purpose
People who live in places where use of THC is absolutely legal
People who want more intense dose of CBD
You must know that none of the above CBD oils is better than the other. The purchase of CBD oil thoroughly depends on the purpose and necessity of the buyer.
Closing thoughts: The Best CBD oil for Pain?
CBD oil treatment for pain alleviation has proven to be quite successful across the world. However, it is important to hold on to one’s patience and let the results show themselves with time. Even so, there is no reason why you shouldn’t give this organic treatment a chance to heal your problems. There are numerous brands that offer CBD oil at affordable prices and good concentration but it is up to you to find the products that address your problems in the best way.
While the research on the same takes a while, it is your personal duty to give yourself nothing but the finest CBD oil. It is critical for anyone trying the products for the first time to focus on the quality of the same. Also, make sure that the products are lab-tested by the third party. Once you are sure about everything, well, then go ahead and buy the product and waste no time in healing yourself! It’s time to let the pain go.
When looking for a new vaping device, we usually want our dreamlike product to be several things: functional, durable, and affordable.
Some people also want their vaporizer to be visually appealing.
Finding a product that satisfies all of these criteria is much harder than you think, but luckily, such solutions do exist. One option that is worth considering in that regard is Vivant Dabox.
Vivant Dabox is hardly a revolutionary product, but it’s a comprehensive solution that can satisfy the needs of many cannabis enthusiasts who consume it frequently. In the review below, I will explore all the fundamentals of this vaping device so that you can get a good overview of whether this is a product that you will want, can afford and use in the long run.
Let’s get started!
1.92” (4.9 cm)
Unboxing Vivant Dabox
Here’s a full list of accessories that you will get once you unbox this vaping device:
One Loading Tool
A USB Cable
Dual Quartz Coil and a Dual Quartz Clapton Coil
One Borosilicate Glass Chamber
The Vivant Dabox Vaporizer itself
The box has no room for additional Vivant Dabox vaping accessories, but the good news is, you won’t need them at all. Everything that you will ever require to get the unit up and running is already included in the box and that’s indeed a wonderful thing to see.
Let’s take a closer look at the product itself now.
Design and features
The first thing that you will notice is that Vivant Dabox is really well built. The build is very solid and durable, and I can add that the whole unit has a great visual appeal as well. It has a convenient wax pen design but it’s not as tall and it can fit anyone’s hand quite easily.
There are some design choices that I don’t like here (for example, I am not a fan of silicone splatter guards), but nonetheless, the whole design gets a solid 9/10 score from me.
You can’t control the temperature levels manually here, but the good news is, you don’t have to. The device has a fixed temperature setting that is carefully optimized to please the needs of even the most demanding cannabis users. You do have the flexibility to finetune the performance via the interchangeable coil system, though (I will talk about that in the lines below).
The unit comes with two interchangeable Dual Quartz coils that you can use to optimize the performance of your vaporizer. That way, you can improve the flavor of your concentrates. If you want rich and potent flavor, you should use the Dual Quartz Rod atomizer as well. Otherwise, if thick clouds are your favorites, you can stick with the Dual Quartz Clapton Coil.
Vivant Dabox comes with a 1500 mAh battery, and once fully charged, the power can last for days on end. Even the most demanding consumers won’t be disappointed as they will be able to enjoy a full day of high-quality vaping.
We have three different lights here – red, blue, and green and they all indicate different battery levels. The charging process doesn’t take long and all you need is one hour of patience.
The great news is, Vivant Dabox is a highly portable unit. You can carry it around as you go and the device slips into any standard backpack. If you’re a frequent traveler or you just admire the fact that you can carry your vaporizer with you and share that experience with like-minded individuals, you will definitely love Vivant Dabox.
The Flip Door feature
The last feature on this list is, by far, my favorite one. Unlike many conventional vaping units, the loading process here is very straightforward. The reason for that simplicity lies in a remarkable feature called the Flip Door. With this addition, you can load your concentrates on the go and without putting any (significant) effort. If there’s one selling point that sets this product apart from its competitors, it would definitely be this one.
The vapor that you’re getting with this vaporizer is not remarkable, but it’s solid enough to provide an enjoyable experience. The clouds have a nice density and the flavor itself is strong and profound.
The only real issue I have here is the lack of consistency. Overall, you can expect better results with the Dual Quartz Rod atomizer whereas the Clapton Coil atomizer will provide an inferior aroma and the heat-up time may also be somewhat longer.
It’s not a deal-breaking situation, but if you’re a perfectionist like me, you’ll want to optimize every detail for maximum performance, which is why I had to note it.
Ease of use
Vivant Dabox is one of the most user-friendly vaporizers that I’ve ever encountered. All you need to do is follow four simple steps – swing the arm open, load the chamber with your cannabis concentrates, press the button five times repeatedly to turn on the device, and finally, press and hold the same button to take a draw. That’s how easy it is!
You may struggle to get the atomizer to slide into place in the arm sometimes, but overall, it’s not a big problem.
The unit is durable and very well built
It comes with an affordable price tag
The portability is outstanding
It is very easy to use
The Flip Door is a feature that you will hardly find in other similar solutions
The vapor quality is good but not consistent
Some people may not like the fact that they can’t tweak the temperature manually
The same people may also struggle with the idea of having silicone splatter guards rather than pure glass
If you’re looking for a functional, durable, and affordable vaporizer, Vivant Dabox is definitely the product for you. Even despite some obvious downsides, it’s a product that both experienced individuals and newcomers alike will enjoy with equal passion.
If you’ve never owned a vaping device before, this is a good starting point. But even if you’ve owned dozens of them already, adding Vivant Dabox to your collection is a goal worth pursuing.
Certain aspects of the U.S. cannabis industry have limited protections from federal interference through annual congressional spending bills. Since the restriction of district-specific earmarks in 2015, lawmakers have used annual appropriations bills (also known as federal spending bills) to extend their policy priorities (or policy prohibitions) by inserting language that prohibits the expenditure of federal funds towards a specific program or activity.
Since 2015, Congress has consistently enacted laws that limit the ability of the Department of Justice (DOJ) from interfering with states that have adopted medical cannabis laws by placing legal restrictions on their spending of federal dollars. Spending bills protecting the medical cannabis industry have to be renewed every year or must be carried forward in the event federal spending bills are not successfully enacted.
Despite this onerous process, this legal baseline has established a consistent policy of respecting states’ rights to set and implement their respective medical cannabis laws by preventing federal agencies, including the DOJ and the Drug Enforcement Agency (DEA), from prosecuting medical cannabis stakeholders operating in compliance with state law. However, this appropriation language doesn’t prevent other federal agencies like the IRS, the Federal Deposit Insurance Corporation (FDIC), or the SEC from taking enforcement actions.
While there’s been progress to expand spending prohibitions to apply to the entire cannabis industry (and not just medical cannabis industry stakeholders), no efforts have yet been successfully signed into law, though the House of Representatives approved this provision in 2019 in a 267-165 vote, including efforts to prevent the DOJ from interfering in any state-legal cannabis business, not just those that are medical in nature.
Former Attorney General Jeff Sessions rescinded a key DOJ policy (commonly referred to as the “Cole Memo”) in 2017, which set forth the DOJ’s enforcement priorities with respect to medical and adult-use cannabis stakeholders, focusing on issues like access by minors. However, since the rescission of this key policy document, the majority of U.S. attorneys in relevant jurisdictions have clarified that they’ll continue to exercise prosecutorial discretion in a manner consistent with the Cole Memo.
When the Cole Memo was first introduced in 2014, the Department of the Treasury Financial Crimes Enforcement Network (FinCEN) implemented guidelines predicated on the Cole Memo to address the bankability of proceeds from state-compliant cannabis activities, referred to as “FinCEN guidance.” The FinCEN guidance sets forth specific standards for banks working with state-compliant cannabis companies to mitigate the risk that these financial institutions would be prosecuted for money-laundering violations. Though the Cole Memo was rescinded, the FinCEN guidance remained in place, which is important for investors.
Changing Federal Law and Politics Around Legalization
For more than a decade, dozens of bills have been introduced in Congress to address federal cannabis reform. Consider these bills to be in two categories. In the first category are bills with the objective of legalizing cannabis at the federal level, either by descheduling cannabis as a Schedule I substance or rescheduling it to a less-restrictive category within the Controlled Substances Act. The second category of bills aims to address all the ancillary issues that have been created by the conflict between federal and state law. These include, but aren’t limited to, access to banking, cash treatment, federal benefits, immigration, veterans, and so on. With this active and evolving legislative environment, the question on everyone’s mind is: When will cannabis be legalized at the federal level and by what legislative mechanism?
Industry advocates are also concerned with another issue: ensuring that existing and future cannabis businesses are treated like other existing businesses without unnecessary discrimination, including access to traditional banking. As cannabis businesses receive more protections from the federal government, they can feel comfortable reinvesting in their communities through inclusive hiring practices and capital infusions. For cannabis entrepreneurs, creating business models that incorporate criminal and social justice pillars within their organizations will benefit from this important element of comprehensive reform at the federal level.
Nevertheless, it’s understandable that for business industry stakeholders and their advocates, the most politically pragmatic opportunity to advance reform is legislation to address access to banking. Under current law, cannabis businesses are often forced to operate in cash. However, there’s a favorable climate to advance legislation that would improve banking access for cannabis businesses.
The most meaningful legislative measure advanced to date is the Secure and Fair Enforcement (SAFE) Banking Act of 2019 (H.R. 1595 | S. 1200). The SAFE Banking Act would create protections for depository institutions that provide financial services to state-compliant cannabis-related businesses and service providers. The SAFE Banking Act would not only codify protections for banks and financial institutions to service the cannabis industry, but it would ensure that licensed and legally operating cannabis businesses in the U.S. have access to traditional financial services. Because the bill allows cannabis businesses to access financial institutions while rectifying the public safety concern posed by cash businesses, SAFE enjoys strong bipartisan support and looks as though it will receive significant attention in both legislative chambers.
Ultimately, the trajectory of federal cannabis reform and the timing of this progress will come down to the complex equation of politics, policy, and personality. From a politics perspective, lawmakers in both chambers— and on both sides of the aisle—are reminded of the growing popularity for federal cannabis reform and the undeniable support of Americans for prohibiting the federal government from interfering with state programs.
Irrespective of the uncertainties in Washington, DC, cannabis entrepreneurs and investors are uniquely positioned to take advantage of early market opportunities, with a low probability of interference from the federal government. As the federal policy landscape moves closer and closer to deciding a post-prohibition regulatory framework, businesses with the right composition of managerial and strategic leadership, as well as sufficient capital, will only continue to improve their valuations and long-term outlook.
Medical patients in Canada have been accessing cannabis products for over a decade, but new laws allowing adult use (aka, consuming cannabis for non-medical reasons), have prompted employers to add cannabis clauses to their workplace impairment policies, typically prohibiting use at work.
But what if you use cannabis therapeutically? Here, certified human resources leader Erin Gratton, who is also the founder and chief learning officer of High Values HR, gives Leafly the lowdown on medical cannabis patients’ rights at work, plus tips for talking to your boss about medical cannabis.
Employee rights and responsibilities
Employers have a duty to accommodate patients who have been authorized to use medical cannabis, just as they would accommodate anyone else taking a prescribed medication. Employers must provide workplace accommodations, to the point of undue hardship (in other words, they must accommodate unless doing so is harmful to the regular business of the company).
That said, if you face barriers to managing health while at work, it’s up to you to approach your boss or HR reps for help.
“I often hear employees say they get really nervous about the level of disclosure required of them; potentially providing medical information can be a scary thing,” says Gratton.
Luckily, you’re not expected to disclose all your personal health business—Gratton recommends visiting the Canadian Human Rights Commission to learn more about the questions your boss can and can’t ask you about medical issues.
Keep employee documents and authorizations up to date
Some employment contracts include clauses requiring mandatory or voluntary disclosure of certain medical information, especially in safety-sensitive roles. Gratton recommends asking questions when reviewing employment documents, and having an open dialogue around a company’s policies.
StatsCan: Over Half a Million Canadians Use Cannabis at Work
And remember—only patients have patients’ rights, meaning you must be medically authorized to use cannabis in order to receive workplace accommodations.
Self-diagnosis is risky in the workplace, says Gratton, and tribunals have generally not been sympathetic towards cases involving self-diagnosis or self-medication. Since employee rights do not extend to adult use (aka recreational consumption), ensure your documentation is up-to-date at all times if you need accommodation.
How to talk weed with your boss
Disclosing health information can be difficult in a work environment, especially when discussing a medication as stigmatized as cannabis. Most workplaces will have a standard policy in place, but if you need further accommodation Gratton says it’s important to make formal requests in writing, and to abide by the company’s internal process.
“Actually use the words ‘workplace accommodation’—it will get their attention,” she advises. “And be prepared to discuss barriers that exist at work and what you need.”
Employees and bosses equally uninformed on medical cannabis rights
An employee isn’t required to share their diagnosis to their employer, but may be asked for a prognosis. Employees can be asked how often they need to medicate, and at what times, and may also be asked about methods of consumption. “Your employer can also ask where your cannabis is sourced from,” says Gratton. “Illicit forms of cannabis would be considered adult use or recreational from an employer perspective,” meaning they don’t count as authorized medicine, regardless of your medical status.
Medicating at work
Get all your ducks in a row, and remember to be responsible and courteous with your medical cannabis consumption at work.
Employees and bosses equally uninformed on medical cannabis rights
“Normalization is new, and people can have concerns that don’t necessarily come from a place of stigma. I think common courtesy goes a long way,” says Gratton. “If someone is complaining about exposure to smoke, or anything else that’s a potential safety issue, we need to take that seriously.”
Avoid accidental impairment when medicating at work by observing the adage start low and go slow. Since new products can have unpredictable outcomes, Gratton recommends test driving them at home first. “I would suggest avoiding trying a new product at work, especially if cannabis is new to you,” she advises. “Choose ideal strains and methods of consumption conducive to your work experience.”
In many ways, the world is looking at Canada to see how employers accommodate medical cannabis patients. Gratton points out that, in many instances, the process of workplace accommodation around medical cannabis has a steep learning curve—on both sides.
“Workplace accommodation is a two-sided process, especially when it comes to the topic of medical cannabis,” she says. “It’s important to have a safe and open dialogue to be able to reach a common understanding on how we can create a safe and inclusive work space for all.”
Ashley Keenan is a content creator and media consultant in the cannabis industry. Ashley writes meaningful, fact-based content to entertain, educate and destigmatize the plant. Ashley is also a skincare expert and spent 10 years as a practicing esthetician, prior to pursuing her masters degree and new career path. Ashley is a passionate medical cannabis advocate and warms hearts with her open and honest health journey.
There are various traditional treatment options that help combat obesity, however, cannabis and different cannabinoids like CBD and THCV have shown to be very useful in helping treat obesity and its symptoms.
Currently, being overweight and obese is categorized as the fifth leading risks for worldwide mortality. Annually, at least 2.8 million people die due to being overweight or obese. Unfortunately, being overweight or obese often plays havoc on one’s well-being and quality of life, especially due to the plethora of health risks and complications that can occur as a result of these diagnoses.
Although millions of adults struggle with being overweight or obese, they’re not the only ones. Nowadays, millions of children are becoming overweight and obese at much younger ages. Specifically, in 2011, more than 40 million children younger than five years old were overweight. There are various traditional treatment options that help combat obesity, however, cannabis and different cannabinoids like cannabidiol (CBD) and tetrahydrocannabivarin (THCV) have shown to be very useful in helping treat obesity and its symptoms.
What to Know About Obesity & The Complications It Can Cause
In general, obesity is much more than just being overweight. Obesity means that an individual’s body fat substantially surpasses the amount of body fat that’s considered healthy. Whereas, being overweight refers to a person who weighs more than the ideal weight for their age and height.
However, both terms are often defined as irregular amounts of disproportionate fat build-up that could negatively impact one’s health and state of being. Overall, being obese poses a higher risk of developing various disabilities, dying at early ages, and experiencing a poor quality of life.
Photo by i yunmai via Unsplash
Some health issues and negative complications that can occur from being obese include the following: depression, anxiety, fatigue, joint and muscle pain, and the incapability of participating in different physical activities. There’s also a higher chance that obese individuals could be diagnosed with type 2 diabetes, different forms of arthritis, ischemic heart disease, and various cardiovascular issues.
In the U.S. alone, it has been found that 37 percent of the adult population is obese, whereas, close to eight percent are close to suffering from severe obesity. Therefore, it’s suggested to take this diagnosis seriously if one wants to prevent additional complications from occurring.
Main Causes of Widespread Obesity
After understanding the prevalence of obesity on a worldwide scale in addition to different complications that can occur from being obese, what are its causes? In most cases, the main cause of being obese consists of an energy imbalance regarding calorie intake and calories used. Over the years, worldwide, there has been a rise in the consumption of energy-dense foods that contain high amounts of unhealthy fat. There has also been a rise in physical inactivity, which is mostly attributable to sedentary lifestyles. Thus, two main causes of obesity include overeating and little to no physical activity.
Other causes include genetics, medications, and various psychological factors. However, certain variables can contribute to obesity including one’s metabolism, lack of sleep duration, and community/neighborhood resources or lack thereof. Additionally, different psychological factors can trigger individuals to become emotional eaters. It’s also common for feelings of anger, sadness, and stress to result in binge-eating, which eventually leads to varying levels of weight gain, especially when one isn’t physically active.
Traditional & Non-Traditional Obesity Treatment Options
In addition, since nearly 1 in every 3 adults are considered obese, and 1 in every 13 adults are considered unhealthily obese, it’s suggested to make certain changes and implement different forms of treatment. Common treatment options that are available include the following: diet changes and healthy eating habits, the incorporation of more exercise and physical activities, the consumption of bariatric medications, and undergoing bariatric surgery, which is normally the last resort.
Aside from these treatment options, it has been discovered that cannabis and several of its valuable cannabinoids can help alleviate many symptoms caused by obesity while also helping obese individuals improve their quality of life and get back on a healthy path. One cannabinoid that’s extremely beneficial for combatting obesity is THCV, which possesses appetite-suppressing properties. THCV also acts as an antagonist of the CB1 and CB2 receptors. Therefore, THCV can block THC, which results in users not experiencing appetite boosts or the munchies.
Additionally, CBD has been found to help regulate one’s appetite. Due to cannabis’s vast medicinal and therapeutic properties though, this plant can help alleviate many symptoms obesity causes such as anxiety, depression, joint, muscle, and back pain, self-esteem and confidence issues, and binge-eating. Besides cannabis itself, certain terpenes play a role in suppressing one’s appetite. The main one known for its appetite-suppressing properties is Humulene.
Photos by: Roberto Valdivia via Unsplash, 377873 via rawpixel
Research Findings Supporting Cannabis’s Ability To Combat Obesity
Over the years, different surveys and studies have been conducted on cannabis users and non-cannabis users who struggle with obesity to discover the role the plant plays in combating obesity. One survey focused on 786 participants, and it found that on average, cannabis shares a link with a lower BMI (body mass index), lower body fat percentage, decreased fasting insulin, and decreased insulin resistance. Then, several other surveys revealed that the prevalence of obesity isn’t as prominent in cannabis users as opposed to non-cannabis users.
Whereas, a set of two representative national surveys found some interesting results, and the following was concluded: “…despite the evidence that cannabis use stimulates appetite in clinical trials and laboratory studies, cannabis users are actually less likely to be obese than non-users in the general population.” However, diet and physical activity weren’t taken into consideration when this conclusion was made. Regarding research studies though, one 2015 study confirmed that cannabis consumption was linked to lower BMI and lower fat mass percentages.
Optimal Cannabis Strains & Consumption Methods to Utilize When Combating Obesity
Moreover, it’s essential for obese individuals to consume the right cannabis strains to reap the benefits they need. In particular, cannabis strains that are high in THCV, CBD, and Humulene are ideal. A few examples include Doug’s Varin, Tahoe OG, Pineapple Purps, and Master Kush, which are known to contain high THCV percentages and high amounts of Humulene.
Generally, most sativa dominant strains possess higher levels of THCV than other strains. Although there are various cannabis consumption methods available like oral ingestion, inhalation, sublingual administration, topical administration, and transdermal usage, it’s up to the individual to decide which one works best for them.
Overall, due to the growing prevalence of obesity in the U.S. and around the world, it’s important to adopt healthy habits and try different treatment options like cannabis usage to combat obesity and/or to prevent obesity. More research must be conducted on THCV and its medicinal benefits, especially its appetite-suppressing properties. However, obese individuals could certainly give cannabis a chance and discover the impact high amounts of THCV, CBD, and/or Humulene can have on their quality of life.
This report studies the Liquid Vaporizer market size (value and volume) by players, regions, product types and end industries, history data 2014-2019 and forecast data 2019-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter’s Five Forces Analysis.
Statistical forecasts in the research study are available for the total Liquid Vaporizer market along with its key segments and development policy. The key segments, their growth prospects, and the new opportunities they present to market players have been mentioned in the report. Moreover, the impact analysis of the latest mergers and acquisition and joint ventures has been included in the report. The report also provides valuable proposals for new project development that can help companies optimize their operations and revenue structure.
Major market player included in this report are:
•Godrej Consumer Products Limited
•Reckitt Benckiser Group PLC
•SC JOHNSON & SON INC
•Spectrum Brand Holdings Inc
The main sources are industry experts from the Liquid Vaporizer industry, including management organizations, processing organizations, and analytical services providers that address the value chain of industry organizations. We interviewed all major sources to collect and certify qualitative and quantitative information and to determine future prospects.
The qualities of this study in the industry experts industry, such as CEO, Vice President, Marketing Director, Technology and Innovation Director, Founder and Key Executives of key core companies and institutions in major Liquid Vaporizer around the world in the extensive primary research conducted for this study we interviewed to acquire and verify both sides and quantitative aspects.
Key questions answered in Liquid Vaporizer market report:
What trends, challenges and barriers are influencing its growth?
How is the ecosystem evolving by segment and region?
Which vertical markets will see the highest percentage of growth?
How do standardization and regulation impact the adoption of Liquid Vaporizer in other sectors?
Who are the key players in Liquid Vaporizer market and what are their strategies?
What strategies should Liquid Vaporizer suppliers and vertical domain specialists adopt to remain competitive?
How to build business strategies by identifying the key market segments poised for strong growth in the future?
Chapter 2. Global Chillers Market Definition and Scope
Chapter 3. Global Chillers Market Dynamics
Chapter 4. Global Chillers Market Industry Analysis
Chapter 5. Global Chillers Market, by Type
Chapter 6. Global Chillers Market, by End-use Industry
Chapter 7. Global Chillers Market, Regional Analysis
Chapter 8. Competitive Intelligence
Chapter 9. Research Process
Note: We can also customize this report and provide individual chapters or a region-wise breakdown report such as North America, Europe or Asia. Also, if you have any special requirements, please let us know and we will offer you the report as you want.
Prominent Market Research has an extensive coverage of diligence verticals of qualitative and quantitative reports across all the industries. In case your needs are not met by syndicated reports untaken by the foremost publishers, we can help you by proposing a customized research elucidation by liaising with different research interventions saving your valuable time and money. We have experienced and trained staff that helps you navigate different options and lets you choose preeminent research solution at most effective cost.
U.S. marijuana retail chain MedMen Enterprises Inc. has been offering vendors shares in its company as payment for cannabis products amid a cash crunch in the industry.
In an email reviewed by MarketWatch, MedMen MMEN, +1.59%MMNFF, -0.62% offered a supplier the full value of the amount owed in MedMen class B non-voting shares, a payment plan for the full value or a one-time cash payment of half the outstanding value. MedMen Chief Financial Officer Zeeshan Hyder confirmed that the company, which announced massive layoffs and other changes late last year, is offering to settle some bills with stock.
“As part of the restructuring, the company has been actively working with its retail vendors on modifying payment terms, which in some cases include stock consideration,” he said in an emailed statement.
MedMen’s situation highlights the difficulties many weed businesses in the U.S. and Canada face in raising financing, as the torrent of cash that had fattened pot company coffers has slowed to a drip. According to data from Viridian Capital Advisors, which tracks cannabis capital raises, the slowdown began in March 2019 and financing cratered by the last two months of last year. Overall, capital raises for public and closely held weed companies fell 20.3% in 2019 from 2018, for a total of $11.3 billion.
“Since late 2015, there has been a mad rush,” Scott Greiper, president of Viridian Capital Advisors, told MarketWatch. “But it has all stopped in 2019.”
MedMen is one of the largest weed retailers in the U.S., with 33 stores across nine states and $44 million in revenue in the fiscal first quarter. Its attractive set of retail properties include a location in Manhattan’s Times Square and a store along the posh Abbot Kinney Boulevard in Venice, Calif. MedMen has likened itself to the “Apple Store of pot,” according to a filing with Canadian regulators, and has advertised heavily in states where such activity is legal.
Paying vendors with stock is part of a larger strategy MedMen is deploying to reduce its overhead and conserve as much cash as possible, according to Hyder.
“The company has been increasingly focused on managing its working capital and has continued to communicate payment status to its key vendors,” Hyder said in his emailed statement.
U.S.-traded shares of MedMen, which trade over the counter and are listed on the Canadian Securities Exchange, have lost 84% of its value in the past year, and now investors could be further diluted by issuing shares to pay its bills. Seaport Global analyst Brett Hundley says that the small amount of stock MedMen is likely to issue won’t affect the stock price that much because there are already more than 588.4 million outstanding shares, according to FactSet.
Hundley says that as funding dried up in the equity markets around September 2019, MedMen was slow to realize that it would be unable to attract investors and, as a result, was late to install cost-cutting measures and other moves necessary to keep the business afloat. Months later, one of its chief sources of capital dried up: according to a December note from Hundley, MedMen management said it doesn’t expect to be able to access the remaining $115 million available to it from $250 million convertible debt deal it inked earlier in 2019. Gotham Green Partners is a weed-focused private equity firm that has backed the likes of Cronos Group Inc. CRON, -1.00%CRON, -1.37% and iAnthus Capital Holdings Inc. IAN, +0.00%IAN, +0.00%.
MedMen has had no choice but to slash costs as the reality of the market set in, including the cancellation of a planned $682 million all-stock acquisition of PharmaCann LLC. After Wall Street reacted with “incredulity” to the company’s selling, general and administrative expenses line of roughly $100 million, according to a note Hundley wrote to clients in December, executives have put in place a plan to cut $70 million of operating expenses by March. The company is also quietly shopping around a license it owns in New York, which may be worth $50 million to $100 million, Hundley says. It’s also selling non-core assets in Arizona and Illinois, and pulling back on capital expenditures and slowing down store construction, according to the company’s filings with Canadian regulators.